Literature DB >> 17075344

Autoimmunity against human tropomyosin isoforms in ulcerative colitis: localization of specific human tropomyosin isoforms in the intestine and extraintestinal organs.

Zafar K Mirza1, Bhagyalakshmi Sastri, Jim J-C Lin, Peter S Amenta, Kiron M Das.   

Abstract

BACKGROUND: Tropomyosins (TMs) are microfilament cytoskeletal proteins, and 5 major human TM isoforms (hTM1-5) are described. hTMs, particularly isoform 5 (hTM5), is capable of inducing autoantibodies and T-cell response in ulcerative colitis (UC). However, cellular localization of hTM isoforms in the colon and in extraintestinal organs commonly involved in UC is unknown.
METHODS: Using isoform-specific monoclonal antibodies, we localized hTMs through immunoperoxidase assay in normal colon (n = 12), small intestine (n = 14), esophagus (n = 10), skin (n = 19), eye (n = 12), gallbladder (n = 16), liver, including bile duct at the porta hepatis (n = 4), lungs (n = 4), and pancreas (n = 4).
RESULTS: There is intense expression of hTM5, but not other isoforms, in the epithelium of the colon, gallbladder, and skin. In the eye, hTM5 is expressed only in the nonpigmented ciliary epithelium. Although extrahepatic and interlobar large ductal biliary epithelium was positive, bile canaliculi at the portal tract are negative. The immunoreactivity in epithelial cells from these organs is diffuse cytoplasmic and along the periphery. In colon epithelium, there is intense expression along basolateral areas and luminal (apical) surface. In the small intestinal epithelium, however, hTM5 expression is weak and distinctly different than in the colon. hTM5 was not detected in the squamous epithelium of the esophagus, although it was strongly positive in the skin. hTM1, hTM2, and hTM3 are localized predominantly in smooth muscle of the intestine and blood vessel wall but not the epithelium. HTM4 is localized in the endothelial cells and basement membrane of the colonic epithelium.
CONCLUSIONS: hTM5 is the predominant isoform in the epithelium of colon and extraintestinal organs commonly involved in UC. The unique expression of hTM5 may allow its interaction with effector immune cells involved in the immunopathogenesis of UC and its extraintestinal manifestations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17075344     DOI: 10.1097/01.mib.0000231573.65935.67

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  6 in total

Review 1.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

2.  Past and Present Behçet's Disease Animal Models.

Authors:  Jermilia Charles; Francis J Castellino; Victoria A Ploplis
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

Review 3.  Pulmonary-intestinal cross-talk in mucosal inflammatory disease.

Authors:  S Keely; N J Talley; P M Hansbro
Journal:  Mucosal Immunol       Date:  2011-11-16       Impact factor: 7.313

Review 4.  Common Amino Acid Subsequences in a Universal Proteome--Relevance for Food Science.

Authors:  Piotr Minkiewicz; Małgorzata Darewicz; Anna Iwaniak; Jolanta Sokołowska; Piotr Starowicz; Justyna Bucholska; Monika Hrynkiewicz
Journal:  Int J Mol Sci       Date:  2015-09-01       Impact factor: 5.923

5.  Cytoskeletal Tropomyosin as a Biomarker in Clostridium difficile Infection.

Authors:  Elena A Usacheva; Lance R Peterson; Katherine Mendoza; Donna M Schora; M Moazzem Hossain; Jian-Ping Jin
Journal:  J Clin Med Res       Date:  2019-01-05

6.  IL18-containing 5-gene signature distinguishes histologically identical dermatomyositis and lupus erythematosus skin lesions.

Authors:  Lam C Tsoi; Mehrnaz Gharaee-Kermani; Celine C Berthier; Tori Nault; Grace A Hile; Shannon N Estadt; Matthew T Patrick; Rachael Wasikowski; Allison C Billi; Lori Lowe; Tamra J Reed; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  JCI Insight       Date:  2020-08-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.